{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:02:23Z","timestamp":1787162543412,"version":"build-2736575974"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T00:00:00Z","timestamp":1571097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2019.01055","type":"journal-article","created":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T01:23:27Z","timestamp":1571102607000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":26,"title":["Clinicopathologic Significance and Immunogenomic Analysis of Programmed Death-Ligand 1 (PD-L1) and Programmed Death 1 (PD-1) Expression in Thymic Epithelial Tumors"],"prefix":"10.3389","volume":"9","author":[{"given":"Joon Seon","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deokhoon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Hyun","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeong Ryul","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Min","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se Jin","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,10,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"10669","DOI":"10.1158\/0008-5472.CAN-07-0539","article-title":"High expression of lymphocyte-associated genes in node-negative HER2+ breast cancers correlates with lower recurrence rates","volume":"67","author":"Alexe","year":"2007","journal-title":"Cancer Res"},{"key":"B2","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/modpathol.2010.234","article-title":"Colorectal cancer prognosis depends on T-cell infiltration and molecular characteristics of the tumor","volume":"24","author":"Dahlin","year":"2011","journal-title":"Mod Pathol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s00262-007-0353-9","article-title":"Leukocyte infiltration and tumor cell plasticity are parameters of aggressiveness in primary cutaneous melanoma","volume":"57","author":"Hillen","year":"2008","journal-title":"Cancer Immunol Immunother."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J Exp Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"S260","DOI":"10.1097\/JTO.0b013e3181f1f62d","article-title":"Epidemiology of thymoma and associated malignancies","volume":"5","author":"Engels","year":"2010","journal-title":"J Thorac Oncol"},{"key":"B9","volume-title":"WHO Classification of Tumors of the Lung, Pleura, Thymus and Heart","author":"Travis","year":"2015"},{"key":"B10","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S1470-2045(18)30062-7","article-title":"Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study","volume":"19","author":"Giaccone","year":"2018","journal-title":"Lancet Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1158\/1078-0432.CCR-18-1449","article-title":"The first-week proliferative response of peripheral blood PD-1(+)CD8(+) T cells predicts the response to anti-PD-1 therapy in solid tumors","volume":"25","author":"Kim","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B12","doi-asserted-by":"publisher","first-page":"S1710","DOI":"10.1097\/JTO.0b013e31821e8cff","article-title":"The Masaoka-Koga stage classification for thymic malignancies: clarification and definition of terms","volume":"6","author":"Detterbeck","year":"2011","journal-title":"J Thorac Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.cllc.2016.03.003","article-title":"A phase III study of durvalumab (MEDI4736) with or without tremelimumab for previously treated patients with advanced NSCLC: rationale and protocol design of the ARCTIC study","volume":"17","author":"Planchard","year":"2016","journal-title":"Clin Lung Cancer."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1038\/modpathol.2016.117","article-title":"Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas","volume":"29","author":"Scheel","year":"2016","journal-title":"Mod Pathol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1038\/modpathol.2017.6","article-title":"Expression of PD-1 and PD-L1 in thymic epithelial neoplasms","volume":"30","author":"Weissferdt","year":"2017","journal-title":"Mod Pathol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e178","DOI":"10.1093\/nar\/gkq622","article-title":"MapSplice: accurate mapping of RNA-seq reads for splice junction discovery","volume":"38","author":"Wang","year":"2010","journal-title":"Nucleic Acids Res"},{"key":"B18","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1186\/1471-2105-11-367","article-title":"A flexible R package for nonnegative matrix factorization","volume":"11","author":"Gaujoux","year":"2010","journal-title":"BMC Bioinformatics"},{"key":"B19","doi-asserted-by":"publisher","first-page":"13.11.1","DOI":"10.1002\/0471250953.bi1311s27","article-title":"Extracting biological meaning from large gene lists with DAVID","volume":"27","author":"Huang da","year":"2009","journal-title":"Curr Protoc Bioinformatics."},{"key":"B20","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nmeth.3337","article-title":"Robust enumeration of cell subsets from tissue expression profiles","volume":"12","author":"Newman","year":"2015","journal-title":"Nat Methods"},{"key":"B21","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1097\/JTO.0000000000000429","article-title":"Diffuse high intensity PD-L1 staining in thymic epithelial tumors","volume":"10","author":"Padda","year":"2015","journal-title":"J Thorac Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.lungcan.2015.03.003","article-title":"Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma","volume":"88","author":"Katsuya","year":"2015","journal-title":"Lung Cancer"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1016\/j.athoracsur.2015.10.044","article-title":"Clinicopathologic and prognostic implications of programmed death ligand 1 expression in thymoma","volume":"101","author":"Yokoyama","year":"2016","journal-title":"Ann Thorac Surg"},{"key":"B24","doi-asserted-by":"publisher","first-page":"4727","DOI":"10.1158\/1078-0432.CCR-16-0434","article-title":"Prognostic value of programmed death ligand 1 and programmed death 1 expression in thymic carcinoma","volume":"22","author":"Yokoyama","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B25","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.lungcan.2016.05.007","article-title":"Expression of programmed death 1 (PD-1) and its ligand (PD-L1) in thymic epithelial tumors: impact on treatment efficacy and alteration in expression after chemotherapy","volume":"99","author":"Katsuya","year":"2016","journal-title":"Lung Cancer"},{"key":"B26","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.humpath.2016.09.023","article-title":"PD-L1, PD-1, CD4, and CD8 expression in neoplastic and nonneoplastic thymus","volume":"60","author":"Marchevsky","year":"2017","journal-title":"Hum Pathol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.lungcan.2016.12.005","article-title":"Analysis of a panel of druggable gene mutations and of ALK and PD-L1 expression in a series of thymic epithelial tumors (TETs)","volume":"104","author":"Tiseo","year":"2017","journal-title":"Lung Cancer"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e0182665","DOI":"10.1371\/journal.pone.0182665","article-title":"Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors","volume":"12","author":"Arbour","year":"2017","journal-title":"PLoS ONE"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/j.jtho.2018.04.013","article-title":"Expression patterns, prognostic value, and intratumoral heterogeneity of PD-L1 and PD-1 in thymoma and thymic carcinoma","volume":"13","author":"Owen","year":"2018","journal-title":"J Thorac Oncol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1111\/1759-7714.12826","article-title":"Impact of PD-L1, transforming growth factor-beta expression and tumor-infiltrating CD8(+) T cells on clinical outcome of patients with advanced thymic epithelial tumors","volume":"9","author":"Duan","year":"2018","journal-title":"Thorac Cancer"},{"key":"B31","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.anndiagpath.2018.03.012","article-title":"PD-L1 immuno-expression assay in thymomas: study of 84 cases and review of literature","volume":"34","author":"Guleria","year":"2018","journal-title":"Ann Diagn Pathol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.lungcan.2018.09.002","article-title":"Different pattern of PD-L1, IDO, and FOXP3 Tregs expression with survival in thymoma and thymic carcinoma","volume":"125","author":"Wei","year":"2018","journal-title":"Lung Cancer"},{"key":"B33","doi-asserted-by":"crossref","DOI":"10.1097\/PAI.0000000000000699","article-title":"Programmed death-ligand 1 (PD-L1) expression in thymic epithelial tumors","volume-title":"Appl Immunohistochem Mol Morphol","author":"Bedekovics","year":"2018"},{"key":"B34","doi-asserted-by":"publisher","first-page":"5830547","DOI":"10.1155\/2018\/5830547","article-title":"Correlation between the expression of PD-L1 and clinicopathological features in patients with thymic epithelial tumors","volume":"2018","author":"Chen","year":"2018","journal-title":"Biomed Res Int"},{"key":"B35","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1136\/jclinpath-2017-204788","article-title":"PD-1 and PD-L1 expression in thymic epithelial tumours and non-neoplastic thymus","volume":"71","author":"Bagir","year":"2018","journal-title":"J Clin Pathol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.athoracsur.2018.08.037","article-title":"Clinicopathologic features of thymoma with the expression of programmed death ligand 1","volume":"107","author":"Hakiri","year":"2019","journal-title":"Ann Thorac Surg"},{"key":"B37","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1002\/cam4.1943","article-title":"The prognostic impact of programmed cell death 1 and its ligand and the correlation with epithelial-mesenchymal transition in thymic carcinoma","volume":"8","author":"Funaki","year":"2019","journal-title":"Cancer Med"},{"key":"B38","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/S1470-2045(18)30144-X","article-title":"Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study","volume":"19","author":"Garassino","year":"2018","journal-title":"Lancet Oncol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1016\/S0140-6736(16)00587-0","article-title":"Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial","volume":"387","author":"Fehrenbacher","year":"2016","journal-title":"Lancet."},{"key":"B40","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N Engl J Med"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1001\/jamaoncol.2017.0013","article-title":"A prospective, multi-institutional, pathologist-based assessment of 4 immunohistochemistry assays for PD-L1 expression in non-small cell lung cancer","volume":"3","author":"Rimm","year":"2017","journal-title":"JAMA Oncol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"3585","DOI":"10.1158\/1078-0432.CCR-16-2375","article-title":"Agreement between programmed cell death ligand-1 diagnostic assays across multiple protein expression cutoffs in non-small cell lung cancer","volume":"23","author":"Ratcliffe","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B43","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.jtho.2016.11.2228","article-title":"PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project","volume":"12","author":"Hirsch","year":"2017","journal-title":"J Thorac Oncol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"6993","DOI":"10.18632\/oncotarget.24075","article-title":"A comparative study of PD-L1 immunohistochemical assays with four reliable antibodies in thymic carcinoma","volume":"9","author":"Sakane","year":"2018","journal-title":"Oncotarget"},{"key":"B45","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13000-016-0494-2","article-title":"Quantitative and qualitative characterization of Two PD-L1 clones: SP263 and E1L3N","volume":"11","author":"Smith","year":"2016","journal-title":"Diagn Pathol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1097\/JTO.0000000000000393","article-title":"The impact of thymoma histotype on prognosis in a worldwide database","volume":"10","author":"Weis","year":"2015","journal-title":"J Thorac Oncol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1038\/modpathol.2016.213","article-title":"Heterogeneous expression of PD-L1 in pulmonary squamous cell carcinoma and adenocarcinoma: implications for assessment by small biopsy","volume":"30","author":"Gniadek","year":"2017","journal-title":"Mod Pathol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2019.01055\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T01:23:30Z","timestamp":1571102610000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2019.01055\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,15]]},"references-count":47,"alternative-id":["10.3389\/fonc.2019.01055"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2019.01055","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,15]]},"article-number":"1055"}}